Insider Selling: REGENXBIO (NASDAQ:RGNX) Insider Sells $216,472.32 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 19,608 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $11.04, for a total transaction of $216,472.32. Following the sale, the insider directly owned 213,009 shares of the company’s stock, valued at $2,351,619.36. This trade represents a 8.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Steve Pakola also recently made the following trade(s):

• On Wednesday, July 1st, Steve Pakola sold 36,725 shares of REGENXBIO stock. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The shares were sold at an average price of $11.02, for a total value of $168,705.18.

REGENXBIO Stock Performance

Shares of RGNX opened at $13.28 on Friday. The business’s fifty day simple moving average is $8.29 and its two-hundred day simple moving average is $9.93. REGENXBIO Inc. has a 12 month low of $5.45 and a 12 month high of $16.19. The company has a market cap of $686.58 million, a price-to-earnings ratio of -2.37 and a beta of 0.90.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). The business had revenue of $6.39 million during the quarter, compared to the consensus estimate of $25.84 million. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%. As a group, research analysts forecast that REGENXBIO Inc. will post -3.69 EPS for the current year.

Institutional Trading of REGENXBIO

Hedge funds have recently bought and sold shares of the stock. Versant Capital Management Inc raised its stake in shares of REGENXBIO by 60.4% in the second quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock worth $33,000 after buying an additional 1,032 shares during the period. Deutsche Bank AG grew its stake in shares of REGENXBIO by 0.8% during the 4th quarter. Deutsche Bank AG now owns 192,582 shares of the biotechnology company’s stock valued at $2,773,000 after acquiring an additional 1,527 shares during the period. Captrust Financial Advisors grew its stake in shares of REGENXBIO by 13.2% during the 4th quarter. Captrust Financial Advisors now owns 15,228 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 1,781 shares during the period. Diversified Trust Co increased its holdings in REGENXBIO by 15.9% in the 1st quarter. Diversified Trust Co now owns 15,499 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 2,121 shares in the last quarter. Finally, Intech Investment Management LLC increased its holdings in REGENXBIO by 12.2% in the 4th quarter. Intech Investment Management LLC now owns 21,367 shares of the biotechnology company’s stock worth $308,000 after acquiring an additional 2,327 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on RGNX. Weiss Ratings restated a “sell (e+)” rating on shares of REGENXBIO in a research note on Monday, June 8th. Leerink Partners lifted their price target on shares of REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Bank of America decreased their price objective on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a report on Friday, May 15th. Robert W. Baird increased their price objective on shares of REGENXBIO from $27.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, June 22nd. Finally, HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of REGENXBIO in a research report on Wednesday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.82.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.